Corcept Therapeutics Incorporated, based in Redwood City, California, announced significant findings from its pivotal Phase 3 ROSELLA trial at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data highlights the effectiveness of relacorilant in combination with nab-paclitaxel for patients suffering from platinum-resistant ovarian cancer, particularly those who have previously undergone treatment with a PARP inhibitor.
The results indicate a notable improvement in progression-free survival (PFS) for patients whose cancer progressed while on or after PARP inhibitor therapy. This demographic typically faces a particularly challenging prognosis, making these findings potentially transformative for treatment options in this patient population.
Details of the ROSELLA Trial
The Phase 3 ROSELLA trial focused on evaluating the safety and efficacy of relacorilant combined with nab-paclitaxel in individuals with platinum-resistant ovarian cancer. This combination therapy aims to address the significant unmet medical need for patients who have limited treatment options due to their cancer’s resistance to standard therapies.
Data presented at ESMO 2025 showed a clear PFS benefit, suggesting that relacorilant could not only improve the quality of life for these patients but also extend survival times. The company emphasized that these findings may offer new hope for individuals battling this aggressive form of cancer.
Corcept also revealed plans to expand the Phase 2 BELLA trial during a poster session at the conference. This trial investigates the effects of relacorilant on different patient populations, further underlining the company’s commitment to advancing treatment options in oncology.
Implications for Future Research
The findings from the ROSELLA trial could lead to new therapeutic strategies for managing platinum-resistant ovarian cancer. As the data continue to unfold, researchers and healthcare professionals are optimistic about the potential of relacorilant as a significant addition to cancer treatment protocols.
In a statement, Corcept highlighted the importance of ongoing research in this area, noting that the results from these trials will inform future clinical decisions and possibly reshape treatment standards for patients facing similar challenges.
The slides from the presentation at ESMO are available for public access, allowing the broader medical community to review the findings in detail. As the landscape of cancer treatment evolves, the focus remains on developing innovative therapies that can effectively combat resistance and improve patient outcomes.
